<DOC>
	<DOCNO>NCT00402779</DOCNO>
	<brief_summary>The goal clinical research study learn erlotinib hydrochloride ( Tarceva√¢ ( OSI-774 ) prevent cancer mouth people high risk develop cancer mouth . The safety drug also study , well drug 's effect different cell body .</brief_summary>
	<brief_title>Erlotinib Prevention Oral Cancer ( EPOC )</brief_title>
	<detailed_description>Erlotinib hydrochloride design block activity enzyme find surface many tumor cell may control tumor growth survival . This may keep tumor grow . If find eligible participate study , randomly assign ( toss coin ) receive either erlotinib hydrochloride placebo . A placebo substance look like study drug active ingredient . Neither investigator know treatment group assign . However , event medical emergency , study chair find group , necessary . You inform group assign , study end . There certainty effect treatment , place group active study drug . While study , take study dose ( either erlotinib hydrochloride placebo ) mouth , tablet form , day . Tablets take morning 1 hour 2 hour meal , medication , vitamin , iron supplement , 7 ounce water . You take study dose around time every day . Every attempt make keep vomiting dose , least 30 minute take . For example , feel nauseated take study dose , anti-nausea medication use . If vomit take study dose , dose take tablet ( ) actually see count ( word , dissolve yet ) . You need note time take dose medication throughout study calendar study nurse give . At Months 1 , 3 , 6 , 9 , 12 , return clinic . You physical exam include measurement vital sign . You careful examination inside mouth.You blood ( 2 teaspoon ) draw routine test check liver function ( 1-2 teaspoon ) . At Months 3 , 6 , 12 , blood ( 2 teaspoon ) draw research test measure level study drug body . Your study doctor ask medication take , feeling ( symptom ) , current smoking alcohol usage . The nurse study coordinator collect medication take , well complete pill diary , every clinic visit . At Months 1 , 3 , 6 , 9 , also give new study medication pill diary . You may also another small biopsy perform inside mouth area cell might become cancerous locate . The biopsy perform doctor sent lab test . At month 3 12 , doctor also count measure red white patch inside mouth . Biopsies take 3 month treatment end 12 month treatment . The tissue test see cell might become cancerous . Following end treatment , return clinic every 6 month 2 year . You complete physical exam , include measurement vital sign . You careful examination inside mouth . You blood draw ( 2 teaspoon ) routine test , check liver function , research test . Your study doctor ask medication take feeling ( symptom ) , current tobacco alcohol use . In addition , final clinic visit , also take part personal interview . During interview , ask question regard socio-demographic information ( age race ) , nutrition habit , current early tobacco use , alcohol use habit , family history cancer , use medication , feel . The interview take 90 minute complete . The purpose interview collect information learn relationship certain factor risk develop cancer mouth . You may contact future order collect information . You may take study able follow doctor ' instruction , serious side effect occur , doctor think best interest leave study . If take study reason , ask return clinic final clinic visit , preferably within 14 day leave study . This investigational study . Erlotinib hydrochloride approve FDA treatment NSCLC . Its use study consider investigational . Approximately 491 patient screen study . Up 120 enrol MD Anderson .</detailed_description>
	<mesh_term>Mouth Neoplasms</mesh_term>
	<mesh_term>Lip Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>1 . Male female patient one following : ( ) loss heterozygosity ( LOH ) 3p14 and/or 9p21 oral IEN patient history curatively treated oral cancer ( b ) LOH 3p14 and/or 9p21 plus one chromosomal region IEN patient oral cancer history . 2 . Participants must confirm diagnosis oral IEN lesion LOH . ( Note : The initial screening biopsy oral IEN lesion LOH must obtain within 12 month study enrollment . If initial diagnostic biopsy LOH &gt; 3 month prior study enrollment , investigator may use clinical judgment order additional screening biopsy assess histopathological change ) . 3 . Age &gt; /= 18 year 4 . ECOG performance status &lt; 2 5 . Participants must normal organ &amp; marrow function define w/in 30 day randomization : CBC w/ differential white cell countacceptable result must include : WBC &gt; 3,000ul , hemoglobin &gt; 10 g/dl , platelet count &gt; 125,000ul , LFTstotal bilirubin &amp; alkaline phosphatase , AST ( SGOT ) &amp; ALT ( SPGT ) w/in &lt; 1.5xULN.Note : At discretion attend physician , participant w/ Gilbert 's disease may still eligible participate event total bilirubin value &gt; 1.5xULN . Kidney functionserum creatinine &lt; 1.5xULN ChemistrySodium &amp; potassium w/in normal institutional limit . 6 . The effect study agent develop human fetus unknown.For reason , WOCBP &amp; men must agree use adequate contraception ( hormonal barrier method birth control ; abstinence ) prior study entry &amp; duration active treatment.Neg.serum pregnancy test WOCBP.Childbearing potential defined woman menses w/in past 12 mths , tubal ligation bilateral oophorectomy.Should woman become pregnant suspect pregnant participating study , inform study physician immediately 7 . Ability understand willingness sign write informed consent document 1 . Patients active cancer cancer within previous two year , exclude oral nonmelanoma skin cancer . 2 . Patients acute intercurrent illness surgery , radiation therapy , chemotherapy within precede 4 week unless fully recover . 3 . Patients document history coagulopathy and/or take warfarin warfarinderivative anticoagulant 4 . Women pregnant ( confirm bHCG applicable ) breastfeed 5 . Any medical psychological condition reason , accord investigator 's judgment , make patient unsuitable participation study 6 . Patients participate experimental therapy study within 3 month enrollment trial 7 . Patients history inflammatory bowel disease 8 . Patients document history interstitial lung disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Oral Cancer</keyword>
	<keyword>Oral IEN Lesion LOH</keyword>
	<keyword>Loss Heterozygosity</keyword>
	<keyword>Intraepithelial Neoplasia</keyword>
	<keyword>Placebo</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>OSI-774</keyword>
</DOC>